Silence Therapeutics (SLN)

• Market cap: $252M
• 1 day: 1.52%
• 5 days: -5.50%
• 1 month: -22.53%
• 3 months: -69.19%
• 6 months: -74.00%
• Year to date: -25.87%
• 1 year: -76.32%
• 5 years: -72.67%
• 10 years: -72.67%

About: Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.

Employees: 109

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

60% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 15

0.72% less ownership

Funds ownership: 20.8% [Q2] → 20.08% (-0.72%) [Q3]

3% less funds holding

Funds holding: 70 [Q2] → 68 (-2) [Q3]

9% less capital invested

Capital invested by funds: $538M [Q2] → $491M (-$46.4M) [Q3]

13% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 15

17% less funds holding in top 10

Funds holding in top 10: 6 [Q2] → 5 (-1) [Q3]

78% less call options, than puts

Call options by funds: $8K | Put options by funds: $36K

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $55 932% upside
• Avg. target: $65 1,120% upside
• High target: $75 1,307% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Patrick Trucchio 0 / 0 met price target	1,307% upside $75	Buy Reiterated	29 Jan 2025
Chardan Capital Keay Nakae 0% 1-year accuracy 0 / 6 met price target	932% upside $55	Buy Maintained	10 Dec 2024